Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-06-15
2009-08-25
Anderson, Rebecca L (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S469000
Reexamination Certificate
active
07579371
ABSTRACT:
Disclosed are methods of treating cancer comprising administering to the animal, a therapeutically effective amount of a heterocyclic compound of Formula VI. The animal is a mammal, preferably a human or a rodent.
REFERENCES:
patent: 5445829 (1995-08-01), Paradissis et al.
patent: 5576012 (1996-11-01), Bauer et al.
patent: 5601845 (1997-02-01), Buxton et al.
patent: 5641515 (1997-06-01), Ramtoola
patent: 5653987 (1997-08-01), Modi et al.
patent: 5654286 (1997-08-01), Hostetler
patent: 5667809 (1997-09-01), Trevino et al.
patent: 5683676 (1997-11-01), Akehurst et al.
patent: 5688529 (1997-11-01), Lidgate et al.
patent: 5707615 (1998-01-01), Cardin et al.
patent: 5707641 (1998-01-01), Gertner et al.
patent: 5726181 (1998-03-01), Hausheer et al.
patent: 5733888 (1998-03-01), Carver et al.
patent: 5756764 (1998-05-01), Fenteany et al.
patent: 5874443 (1999-02-01), Kiely et al.
patent: 5886210 (1999-03-01), Rayle et al.
patent: 5922683 (1999-07-01), Or et al.
patent: 6133308 (2000-10-01), Soucy et al.
patent: 6147223 (2000-11-01), Fenteany et al.
patent: 6214862 (2001-04-01), Fenteany et al.
patent: 6271199 (2001-08-01), Brand et al.
patent: 6294560 (2001-09-01), Soucy et al.
patent: 6335358 (2002-01-01), Fenteany et al.
patent: 6350759 (2002-02-01), Casara et al.
patent: 6458825 (2002-10-01), Fenteany et al.
patent: 6500825 (2002-12-01), Lan et al.
patent: 6506787 (2003-01-01), Fujishita et al.
patent: 6509331 (2003-01-01), Audia et al.
patent: 6566553 (2003-05-01), Soucy et al.
patent: 6645999 (2003-11-01), Schreiber et al.
patent: 6794516 (2004-09-01), Soucy et al.
patent: 6838477 (2005-01-01), Schreiber et al.
patent: 6849743 (2005-02-01), Soucy et al.
patent: 7144723 (2006-12-01), Fenical et al.
patent: 7176232 (2007-02-01), Fenical et al.
patent: 7176233 (2007-02-01), Fenical et al.
patent: 7179834 (2007-02-01), Fenical et al.
patent: 7183417 (2007-02-01), Corey
patent: 7276530 (2007-10-01), Potts et al.
patent: 2001/0051654 (2001-12-01), Elliott et al.
patent: 2005/0049294 (2005-03-01), Palladino et al.
patent: 2005/0203162 (2005-09-01), Xiao et al.
patent: 2006/0008852 (2006-01-01), Fenical et al.
patent: 2006/0229353 (2006-10-01), Stadler et al.
patent: 2006/0264495 (2006-11-01), Palladino et al.
patent: 2006/0287520 (2006-12-01), Danishefsky et al.
patent: 2007/0155815 (2007-07-01), Fenical et al.
patent: 2007/0225350 (2007-09-01), Anderson et al.
patent: 2008/0070273 (2008-03-01), Fenical et al.
patent: 2008/0070969 (2008-03-01), Potts et al.
patent: 2429163 (2002-06-01), None
patent: WO 96/32105 (1996-10-01), None
patent: WO 99/09006 (1999-02-01), None
patent: WO 99/15183 (1999-04-01), None
patent: WO 00/23614 (2000-04-01), None
patent: WO 02/47610 (2002-06-01), None
patent: WO 2004/043374 (2004-05-01), None
patent: WO 2004/071382 (2004-08-01), None
patent: WO 2005/002572 (2005-01-01), None
patent: WO 2005/003137 (2005-01-01), None
patent: WO 2005/099687 (2005-10-01), None
patent: WO 2006/005551 (2006-01-01), None
patent: WO 2006/028525 (2006-03-01), None
patent: WO 2006/060609 (2006-06-01), None
patent: WO 2006/060809 (2006-06-01), None
patent: WO 2006/118973 (2006-11-01), None
patent: WO 2007/021897 (2007-02-01), None
patent: WO 2007/033039 (2007-03-01), None
Voskoglou-Nomikos et al. Clinical Cancer Research 2003, 9, 4227-4239.
Shoemaker, R.H. Nature Reviews Cancer 2006, 6, 813-823.
Adams, Julian, “Proteasome Inhibitors as New Anticancer Drugs”,Curr. Opin. Oncol., (2002) 14:628.
Adams, et al., “Proteasome Inhibitors: A Novel Class of Potent and Effective Antitumor Agents”,Cancer Res., (1999) 59:2615.
Adams, J., “The Development of Novel Targeted Therapeutics for Treatment of Multiple Myeloma Research Roundtable”,Euro. J. Haematology, (2003) 70:263-272.
Alessandri, et al., “Mobilization of Capillary Endothelium in Vitro Induced by Effectors of Angiogenesis in Vivo”,Cancer Res., (1983) 43(4):1790-1797.
Alm, et al., “Effects of Topically Applied PGF2 and its Isopropylester on Normal and Glaucomatous Human Eyes”,Prog. Clin. Biol. Res., (1989) 312:447-58.
Beers et al., “The Merck Manual of Diagnosis and Therapy,” 17th Ed. 1999, published by Merck Research Laboratories, pp. 397-398, 948-949, 1916 and 1979-1981.
Beers, et al., “Bacterial Diseases”The Merck Research Laboratories, Whitehouse Station N.J. XP002318189 157(13): 1157-1158, 1999.
Beers, et la., “Parasitic Infections”Merck Research Laboratories, Whitehouse Station N.J. XP002318189. 1241-1252, 1999.
Bernan, et al., “Marine Microorganisms as a Source of New Natural Products”,Advances in Applied Microbiology, (1997) 43:57-90.
Bhalla, et al., “High-Dose Mitoxantrone Induces Programmed Cell Death or Apoptosis in Human Myeloid Leukemia Cells”,Blood, (1993) 82(10):3133-3140.
Bicknell, et al., “Tumour Angiogenesis”,Oxford University Press, New York (1997) pp. 5 Content.
Blum, et al., “Adriamycin: A New Anticancer Drug with Significant Clinical Activity”,Ann Intern Med, (1974) 80:249-59.
Blunt, et al., “Marine Natural Products”,Nat. Prod. Rep., (2003) 20:1-48.
Bodart, et al., “Anthrax, MEK and Cancer”,Cell Cycle, (2002) 1:10-15.
Bradley, et al., “Identification of the Cellular Receptor for Anthrax Toxin”,Nature, (2001) 414:225-9.
Bull, et al., “Search and Discovery Strategies for Biotechnology: the Paradigm Shift”,Microbiol Mol. Biol. Rev., (2000) 64:573-606.
Carey, Francis, “Organic Chemistry”, 2d ed.,McGraw Hill, Inc., New York (1992) 328-331.
Chauhan, et al., “A Novel Orally Active Proteasome Inhibitor Induces Apoptosis in Multiple Myeloma Cells with Mechanisms Distinct from Bortezomib”,Cancer Cell, (2005) 8:407-19.
Chauhan, et al., “A Novel Proteasome Inhibitor NPI-0052 as an Anticancer Therapy,”British Journal of Cancer, (2006) 95(8):961-965.
Cheng, et al., “Arenaric Acid, a New Pentacyclic Polyether Produced by a Marine Bacterium (Actinomycetales)”,J. Natural Products, (1999) 62:605-607.
Cheng, et al., “Luisols A and B, New Aromatic Tetraols Produced by an Estuarine Marine Bacterium of the GenusStreptomyces(Actinomycetales)”,J. Natural Products, (1999) 62:608-610.
Claverol, et al., “Mapping and Structural Dissection of Human 20 S Proteasome Using Proteomic Approaches”,Mol Cell Proteomics, (2002) 1:567-78.
Colquhoun, et al, “Rapid Characterization of Deep-Sea Actionmycetes for Biotechnology Screening Programmes”,Antonie Van Leeuwenoek, Dordrecht, (2000) 77:359-367.
Colquhoun, et al., “Novel Rhodococci and Other Mycolate Actinomycetes From the Deep Sea”,Antonie van Leeuwenhoek, (1998) 74:27-40.
Colquhoun, et al., “Taxonomy and Biotransformation Activities of Some Deep-Sea Actinomycetes”,Extremophiles, (1998) 2:269-277.
Crane, et al., “A Novel Enantioselective Synthetic Route to Omuralide Analogues with the Potential for Species Selectivity in Proteasome Inhibition”,Organic Letters, (2001) 1395-1397.
Cragg, et al. “Chemical Diversity: A Function of Biodiversity”,Trends Pharmacol Sci, (2002) 23:404.
Crueger, et al., “Biotechnology: A Textbook of Industrial Microbiology”, 2nd ed.,Science Tech Publishers, (1989) Chapter 2:5-8.
Cusak, et al., “Enhanced Chemosensitivity to CPT-11 with Proteasome Inhibitor PS-341: Implications for Systemic Nuclear Factor-kB Inhibition”,Cancer Res., (2001) 61:3535-64.
Cusak, et al., NPI-0052 Enhances Tumoricidal Response to Conventional Cancer Therapy in a Colon Cancer Model,Clin Cancer Res., (2006) 22:6758-64.
Davidson, Bradley S., “New Dimensions in Natural Products Research: Cultured Marine Microorganisms”,Current Opinion in Biotechnology, (1995) 6:284-291.
Decker, et al., “Inhibition of Caspase-3-mediated Poly (ADP-ribose) Polymerase (PARP) Apoptotic Cleavage by Human PARP Autoantibodies and Effect on Cells Undergoing Apoptosis”,J. Biol. Chem., (2000) 275(12):9043-
Macherla Venkata Rami Reddy
Neuteboom Saskia Theodora Cornelia
Palladino Michael
Potts Barbara Christine
Anderson Rebecca L
Knobbe Martens Olson & Bear LLP
Nereus Pharmaceuticals Inc.
Nolan Jason
LandOfFree
Methods of using [3.2.0] heterocyclic compounds and analogs... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of using [3.2.0] heterocyclic compounds and analogs..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of using [3.2.0] heterocyclic compounds and analogs... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4074384